Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma

Stopped early · Phase 2

Conditions studied: Multiple Myeloma and Plasma Cell Neoplasm

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining arsenic trioxide and dexamethasone in treating patients who have recurrent or refractory stage II or stage III multiple myeloma.

Key facts

Study ID

NCT00017069

Run by

CTI BioPharma

Starts

2001-02-01

Expected to finish

2005-01-01

Last updated by the study team

2020-10-05

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Arizona Clinical Research Center — Tucson, Arizona, United States
• Highlands Oncology Group - Springdale — Springdale, Arkansas, United States
• St. Joseph Hospital Regional Cancer Center - Orange — Orange, California, United States
• Stockton Hematology Oncology Medical Group — Stockton, California, United States
• Rocky Mountain Cancer Centers - Midtown — Denver, Colorado, United States
• Pasco Pinellas Cancer Center - Tarpon Springs — Tarpon Springs, Florida, United States
• Winship Cancer Institute of Emory University — Atlanta, Georgia, United States
• Mountain States Tumor Institute - Boise — Meridian, Idaho, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• Texas Cancer Care — Fort Worth, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.